



2026 Annual General Meeting

DOD Biotech Public Company Limited

Friday, 10 April 2026 at 14:00 hrs.

By the electronic channel (E-AGM)

At Head office's meeting room

No.111 Moo 2 Tha Chin Sub-District, Samutsakhon District,

Samutsakhon 74000

Registration will be started on April 2, 2026 at 8:30 hrs.

Attendance will be started on April 10, 2026, at 12:00 hrs.

DOD-E033/2569

March 17, 2026

Subject Invitation to the Annual General Meeting of Shareholders for the year 2026

To The Shareholders of DOD Biotech Public Company Limited

Attachments

1. 56-1 One Report and Financial Statement for the year ended 31 December 2025 in QR Code format
2. The brief profiles of the directors due to retire by rotation and to be nominated for re-election
3. The brief profiles of the persons nominated as auditors for 2026
4. Profile of the independent director proposed as a proxy
5. Provisions of the Articles of Association and law relating to Shareholders meetings
6. Proxy forms A, B, and C
7. The requisition form for 2025 Annual Report Form 56-1 One Report in printed format
8. Registration procedure for e-meeting and Identification required for meeting attendance
9. Additional documents to confirm the right to attend the Annual General Meeting of Shareholders for the year 2026 by means of the electronic channel (E-AGM), granting of proxy, and the cancellation of proxy
10. Privacy Notice for the Shareholders' Meeting

According to the resolutions of the Board of Directors of DOD Biotech Public Company Limited (the "Company"), a meeting of Annual General Meeting of Shareholders for the year 2026 ("AGM 2026") will be held on Friday, April 10, 2026, at 14:00 hrs. The meeting will be conducted solely via electronic media transmission (E-AGM) from the conference room at the Company's headquarters, located 111 Moo 2 Tha Chin Sub-District, Samutsakhon District, Samutsakhon 74000 Thailand. The agendas to consider and approve are as follows:

Agenda 1 To consider and acknowledge the Company's performance for the year 2025

The Board's Opinion: The Board of Directors deems it appropriate to propose to the AGM 2026 to consider and acknowledge the Company's performance and significant changes for the year 2025.

Agenda 2 To consider and approve the Company's audited the financial statements for the year ended December 31, 2025.

The Board's Opinion: The Board of Directors deems it appropriate to propose to the AGM 2026 to consider and approve the Company's audited

Agenda 3 To consider and approve the allocation of net profit as legal reserve and the dividend payment for the 2025 operating results.

The Board's Opinion: The Board of Directors deemed it appropriate to propose to the AGM 2026 to consider the allocation of net profit as a legal reserve for the year 2025 in the amount of 1,280,000.00 Baht (not less than 5% of net profit), and to consider and approve the dividend payment from the 2025 net profit to the Company's shareholders in cash at the rate of 0.05 Baht per share, totaling 22,520,714.25 Baht. The record date to determine the list of shareholders entitled to receive the dividend is scheduled for March 16, 2026, with the dividend payment to be made by May 5, 2026.

However, the right to receive such dividend remains uncertain as it is subject to approval by the Shareholders' Meeting.

Agenda 4 To consider and approve the amendment of the Company's Objectives and the amendment of the Memorandum of Association, Clause 3, to be consistent with the amendment of the Company's Objectives.

The Board's Opinion: The Board of Directors deemed it appropriate to propose to the AGM 2026 to consider and approve the amendment of the Company's objectives by adding objectives to cover the business of investing in securities, debt instruments, bonds, debentures, investment units, mutual funds, private funds, provident funds, and all types of financial instruments, both domestically and internationally (for the purpose of the Company's own asset management, not for engaging in securities business under the law on securities and exchange) to promote responsible investment according to ESG principles and create sustainable asset value for the Company in the long term, including the proposal to amend the Company's Memorandum of Association, Clause 3, to be consistent with the said amendment of objectives.

Agenda 5 To consider the reduction of the unissued registered capital and the amendment of the Memorandum of Association, Clause 4, to be consistent with the reduction of the Company's registered capital.

The Board's Opinion: The Board of Directors deemed it appropriate to propose to the AGM 2026 to consider and approve the reduction of the Company's registered capital by the amount of 118,264,418.00 Baht, from the original registered capital of 343,471,560.50 Baht to the new registered capital of 225,207,142.50 Baht (which is equal to the current paid-up capital), by means of cancelling 236,528,836.00 unissued registered ordinary shares with a par value of 0.50 Baht per share, which were originally allocated to accommodate the issuance and offering of newly issued ordinary shares to a limited number of persons (Private Placement) and to accommodate the rights adjustment of the DOD-W2 warrants, including the proposal to amend the Company's Memorandum of Association, Clause 4, to be consistent with the said reduction of registered capital

Agenda 6 To consider and approve the appointment of the directors those retired by rotation to re-elect the aforementioned to be the Company's director for another term.

The Board's Opinion: The Board of Directors, in agreement with the Nomination and Remuneration Committee, deems it appropriate to propose to the AGM 2026 to consider and approve the re-election of directors who are due to retire by rotation. Out of the total six directors, two directors, namely 1. Mrs. Apaporn Kosolkul and 2. Mr. Pongtep Thithapand shall be re-elected for another term.

For the 2026 Annual General Meeting of Shareholders, the Company provided an opportunity for shareholders to nominate qualified candidates for election as directors. This nomination period was open for the Board of Directors' advance consideration from February 4, 2026, to February 26, 2026. However, no shareholders proposed any director nominees during the specified period.

The Board of Directors has deliberately considered and was of the view that the directors, who will be retired by rotation as mentioned above, meet all requirements stipulated in PCA, relevant regulations

of the Capital Market Supervisory Board and the Company's policy on the nomination of directors. It is thus deemed appropriate to propose to the AGM to consider and re-elect the aforementioned two (2) persons to be the Company's director for another term.

Agenda 7 To consider and approve the fixing of the director's remuneration for the year 2026.

The Board's Opinion: The Board of Directors deemed it appropriate to propose to the AGM 2026 to consider and approve the fixing of the remuneration of the Board of Directors and the committees for the year 2026 in the amount of not exceeding 5.0 million Baht, with no additional benefits, same as the previous year. For Board meetings, independent directors and directors who are not employees will receive a meeting allowance of 5,000 Baht per time. However, directors who are employees will not receive monthly remuneration or meeting allowances. Details are as follows:

Position	Monthly remuneration (Baht)	
	2025	2026 (Year of proposal)
Chairman of Board of Directors	35,000	35,000
Chairman of Audit Committee	70,000	70,000
Chairman of Nomination and Remuneration Committee	20,000	20,000
Member of Audit Committee	45,000	45,000
Member of Nomination and Remuneration Committee	5,000	5,000
Directors (who are not employees of the Company)	20,000	20,000

The company's director compensation policy focuses on transparency and fairness. Compensation is determined based on duties, responsibilities, experience, and the value each director contributes to the organization. Payment levels are benchmarked against industry peers of a similar size to ensure they are sufficient to attract and retain high-quality personnel. The criteria-setting process is reviewed by the Nomination and Remuneration Committee before being presented for annual approval at the shareholders' meeting. Notably, directors who are also employees receive only meeting allowances and do not receive monthly compensation in their capacity as directors.

Agenda 8 To consider and approve the appointment of the auditors and fixing the audit fee for the year 2026.

The Board's Opinion: The Board of Directors, in agreement with the Audit Committee, deems it appropriate to propose to the AGM 2026 to consider and approving the appointment of the auditors from EY Office Limited ("EY") as the auditors of the Company for the year 2026, the auditors' name is as follows: [Detailed in Attachment 3.](#)

1. Mrs. Phonnard Phaocharean Certified Public Accountant no. 5238
2. Ms. Sumesa Tangyoosuk Certified Public Accountant no. 7627
3. Ms. Sineenart Jirachaikhuan Khan Certified Public Accountant no. 6287

The Audit Committee deems it appropriate to propose to the AGM 2026 to consider and approving the remuneration for auditors for the year 2026 not exceed 2.5 million Baht, excluding any other services that the Company will pay for actual services rendered (in 2025, it was 2,130,000 Baht). The details are as follows:

Service Scope	Fee (Baht)	
	2025	2026 (Year of proposal)
Year-end financial statement audit	1,560,000	1,560,000
Quarter 1	180,000	180,000
Quarter 2	180,000	180,000
Quarter 3	180,000	180,000
Total	2,100,000	2,100,000

Agenda 9 Other business (if any)

The Board's Opinion: The Board includes this agenda to provide an opportunity for shareholders to inquire about operations or offer suggestions. No resolutions will be passed on matters not specified in the notice, except as provided by law.

Therefore, the Company cordially invite you, as a shareholder, to attend the meeting as scheduled above. The Company has designated the list of shareholders entitled to attend the Annual General Meeting of Shareholders for the year 2026 (Record Date) on March 16, 2026. The Company has published the meeting documents on its website since March 17, 2026, accessible at <http://www.dodbiotech.com>, under the "Investor Relations/ Publication/ Shareholders' Meetings" section.

Shareholders, who wish to attend the meeting in person or by a proxy to whom is not a director of the Company and vote on their behalf, are able to register through an electronic system. The registration system will be open for operation from 2 April 2026 at 8.30 hours. The system will close the registration on April 10, 2026 until the meeting is closed. The electronic conference system will be available for access on April 10, 2026 at 12.00 hours (2 hours prior to the meeting). Shareholders or proxies can use the Username and Password received from the registration to access and follow the manual in the system. *Detailed in Attachment 8.*

For the preservation of the shareholder's rights and benefits, any shareholders who are unable to attend the meeting in person may appoint an independent director of the Company as a proxy to attend the meeting and vote on their behalf. Please fill in the details and execute the proxy form which is enclosed herewith, and specify, Mr. Dusit Chongsuttanamanee Independent Director as a proxy *Detailed in Attachment 4.* Kindly send the proxy form and supporting document to Company's registered office, 111 Moo 2 Tha Chin Sub-district, Samutsakhon District, Samutsakhon 74000 within 9 April 2026 at 16.00 hours.

Please be informed accordingly.

Respectfully yours,

-- Signature --

Mrs. Apaporn Kosolkul
 Chairman of the Board of Directors

56-1 One Report and Financial Statement for the year ended 31 December 2025 in QR code format



The brief profiles of the directors due to retire by rotation and to be nominated for re-election



Name : Mrs. Apaporn Kosolkul

Current Position : Chairman of the Board / Member of the Audit Committee / Member of the Remuneration and Nomination Committee and Independent Director

Proposed Position : Non-Executive Director

Age : 64 years old

Nationality : Thai

Education : Bachelor of Humanities and Social Sciences, Prince of Songkla University

Training attended with regard to roles and responsibilities of corporate directors :

- Capital Market Leader Program, Class 19, Capital Market Academy
- The Executive Program in Energy Literacy for a Sustainable Future, Class 7, Thailand Energy Academy
- Director Accreditation Program (DAP) Class 133/ 2017
- Poom Palung Pandin Program, Class 2
- Ultra Wealth course, Class 2

Possession of DOD shares : 0.02%

Present Position in Listed Company : N/A

Present Position in a None-Listed Companies :

- 2023 – Present Honorary Advisor, Phum Phalang Phaendin Association
- 2023 – Present Advisor of Corporate Communications Executive, The Mall Group Company Limited
- 2022 - Present Advisor of Public Relations Marketing, KS Chemical (Thailand) Company Limited
- 2022 – Present: Chairman of the Board, DOD Biotech Public Company Limited
- 2022 – Present: Advisory, The Thai Dairy Industry Company Limited
- 2017 - Present Business owner, A La Place Khao Yai
- 2015 - Present Marketing Advisor, Pioneer Logistics Company Limited
- 2015 – Present: Member of the Audit Committee, Member of the Remuneration and Nomination Committee, and Independent Director, DOD Biotech Public Company Limited
- 2015 – Present Columnist (Pseudonym : Somchaba), Thairath Newspaper
- 2012 – Present Columnist (Pseudonym : Supergirl), Thairath Newspaper
- 2011 – Present Business Owner Spirit Art 2011 Company Limited
- 1996 – Present Columnist (Pseudonym : Seeka Ang), Thairath Newspaper

Work Experiences	:	2021 - 2023	Advisor to the Committee on Driving the Draft Act on the Prevention of Recidivism of Violent Offenders, Ministry of Justice
		2021-2023	Audit Committee, Nominating and Compensation Committee, and Independent Director, CMO Public Company Limited
		1988-1996	Assistant Head of News, Political News Rewrite, Thairath Newspaper
		1983-1987	Reporter, Royal Government House, Ministry of the Royal Household, and Special Reporter, Front Page News, Thairath Newspaper
Present Position in a similar establishment to the company for potential conflict of interests	:	- None -	
Appointment Date as Company Director	:	24 December 2015	
Directorship Positions in the Company	:	1 st Term: 24 December 2015 – 22 February 2018 2 nd Term: 23 February 2018 – 23 April 2020 3 rd Term: 24 April 2020 – 29 April 2021 4 th Term: 29 April 2021 – 18 April 2023 5 th Term: 19 April 2023 – Present (Total: 10 years, 2 months)	
Other Positions in the Company	-	- Audit Committee: 24 December 2015 – Present (10 years, 2 months) - Nomination and Remuneration Committee: 24 December 2015 – Present (10 years, 2 months)	
Meeting Attendance in 2025	:	2025 Annual General Meeting of Shareholders (AGM) 1/1 meetings (100%) Board of Directors Meeting 11/11 meetings (100%) Audit Committee Meeting 4/4 meetings (100%) Nomination and Remuneration Committee Meeting 3/3 meetings (100%)	

Key Achievements in 2025

1. **Approval of the Strategic Plan for Production Process Automation**
Reviewed and approved the capital expenditure (CAPEX) for AI-integrated machinery and automated systems. This initiative aims to enhance competitive advantages, reduce long-term production costs, and provide a sustainable solution to the skilled labor shortage.
2. **Enhancing Governance and Internal Control via Digital Technology**
As a member of the Audit Committee, I spearheaded the implementation of a digital auditing system. This enhances the accuracy of real-time financial monitoring and risk assessment, effectively reducing the potential for corporate errors and fraud.

3. Restructuring Compensation and Succession Planning for Sustainability

As a member of the Nomination and Remuneration Committee, I oversaw the development of a comprehensive Executive Succession Plan and updated the compensation structure to align with Sustainability and Profitability Key Performance Indicators (KPIs).

4. Proactive Risk Management Amidst Economic Volatility

Supervised a holistic risk assessment, focusing particularly on foreign procurement risks and currency fluctuations. I also established a robust hedging strategy to maintain the company's financial stability.

5. Promoting Corporate Governance and Stakeholder Value Creation

Emphasized operations based on Good Corporate Governance principles by promoting transparent disclosure and cost-effective budget management to build trust among investors and business partners.



Name : Mr. Pongtep Thithapand

Current Position : Member of the Audit Committee /
 Member of the Remuneration and Nomination Committee and
 Independent Director

Proposed Position : Non-Executive Director

Age : 67 years old

Nationality : Thai

Education : - Master of Arts in Economic Laws Program (M.A.), Chulalongkorn University
 - Master's degree in Master of Public Administration, National Institute of Development Administration
 - Bachelor of Laws, Ramkhamhaeng University

Training attended with regard to roles and responsibilities of corporate directors : Diploma, The National Defence Course Class, Class 54, National Defence College
 Director Certification Program (DCP) Class 125/2009

Possession of DOD shares : – None –

Present Position in Listed Company : – None –

Present Positions in Non-Listed Companies : – None –

Work Experience : 2013 – 2024 Member of the Corporate Governance Committee, Gunkul Engineering Public Company Limited
 2022 – 2023 Director, Sahacogen (Chonburi) Public Company Limited.
 2019 – 2020 Director, PTT Natural Gas Distribution Co., Ltd.
 2015 – 2017 Director, Total Industrial Services Company Limited
 2010 – 2015 Director, PTT LNG Company Limited (Subsidiary of PTT)

Positions in Competing or Related Businesses (Potential Conflicts of Interest) : – None –

Appointment Date as Company Director : December 24, 2015

Independent Director 1st time : 1st Term: December 24, 2015 – March 22, 2017
 2nd Term: March 22, 2017 – April 23, 2020
 3rd Term: April 24, 2020 – April 18, 2023
 4th Term: April 19, 2023 – Present (10 years, 2 months)

Meeting Attendance in 2025	: Board of Directors: 11/11 meetings (100%)
Other Positions in the Company	: - Audit Committee: December 24, 2015 – Present (10 years 2 months) - Nomination and Remuneration Committee: December 24, 2015 – Present (10 years 2 months)
Meeting Attendance in 2025 of other Positions in the Company	: 2025 Annual General Meeting of Shareholders (AGM): 1/1 meetings (100%) Board of Directors Meetings: 11/11 meetings (100%) Audit Committee Meetings: 4/4 meetings (100%) Nomination and Remuneration Committee Meetings: 3/3 meetings (100%)

Key Achievements in 2025

- 1. Strategic Investment Approval for Production Capacity Enhancement**
 Reviewed and approved the budget for Advanced Automation machinery to improve production efficiency, reduce waste, and support the expansion of the new customer base. The initiative is projected to increase production capacity by 20–30% within the next fiscal year.
- 2. Financial Integrity and Transparency Oversight**
 As a member of the Audit Committee, I performed quarterly and annual reviews of financial statements in collaboration with external auditors. This ensures that financial reporting complies with accounting standards and provides full, transparent disclosure to all stakeholders.
- 3. Foundation of Enterprise Risk Management (ERM)**
 Developed and reviewed the Risk Management Framework, focusing on supply chain risks and energy cost volatility. I also established mitigation measures to minimize potential impacts on the company's net profit.
- 4. Compensation Structure Development and Succession Planning**
 As a member of the Nomination and Remuneration Committee, I conducted a review of the compensation structure to ensure it is reasonable and aligned with performance (Performance-based Pay). Additionally, I oversaw the Succession Plan for senior executives to ensure business continuity.
- 5. Driving Sustainable Growth (ESG Framework)**
 Promoted Good Corporate Governance by integrating Environmental and Social (E&S) concepts into the procurement of energy-efficient machinery and sustainability risk management. This initiative enhances the corporate image and improves access to lower-cost financing.

Additional Qualification for independent director (As stipulated by the Notification of the Capital Market Supervisory Board No. TorJor. 39/2016)

Type of relationship

- Not having kind relationship including spouse of child of other directors, of an executive, major shareholder, controlling person, or person to be nominated as director, executive or controlling person of the Company or its subsidiary.
- Not being a director appointed as representative of the Board of Directors, major shareholder or shareholder who is related to a major shareholder of the Company

Having the following relationship with the Company, its parent company, subsidiary company, associate company, same-level subsidiary company, major shareholder or controlling person at present or during the past 2 years

- Not taking part in the management and/or being an employee, staff member, advisor who receives a regular salary or is a controlling person as stipulated in Independent Director Qualification.
- Not being professional services provider, e.g., auditor, partner of an audit firm, legal advisor, financial advisor.
- Not having significant business relation and neither is nor has ever been a significant shareholder or controlling person in a manner that may interfere with his/her independent judgment.

Qualification of Directors

- The qualifications are complete as specified by the company/laws /relevant regulations* and are suitable for the company's business operations.
- The committee has reviewed and determined that the proposed individual for independent director position possesses qualifications in accordance with the relevant laws and requirements regarding independent directors.

***Laws /Relevant Regulations:**

- Public Limited Companies Act, B.E. 2535, section 68
- The Securities and Exchange Act B.E.2535, section 89/3 and the Notification of the Securities and Exchange Commission No. KorJor. 3/2017 regarding the Lack of Trustworthiness of Directors and Managing Directors
- Articles of Association, the Corporate Governance Principles as disclosed in the PTT 56-1 One Report

The brief profiles of the persons nominated as auditors for 2026**Mrs. Phunnard Phaochajean**

Partner

EY Office Limited

Certificated public accountant number 5238

- Education** : Master of Business Administration, Kasetsart University
Bachelor of Accounting, Thammasat University
- Experience in the last five years** : 2016 – Present: Assurance Partner, EY Office Limited
- Qualification** : Certified Public Accountant (Thailand), Auditor Approved by the office of The Securities and Exchange Commission of Thailand and The Stock Exchange of Thailand, Fellow of Thailand Federation of Accounting Professions (TFAC) and Qualified sub-committee on auditing practice testing.
- Relationship with or Interest in (except for the audit service) the Company, Subsidiaries, Executives, Major Shareholders, or their Related Persons Capable of Undermining the Ability to Perform Duties Independently** : - None -
- Contact Details** : EY Office Limited
1875 One Bangkok Tower 3, Level 34 - 37, Rama 4 Road,
Kwang Lumpini, Khet Pathumwan Thailand, Bangkok 10330
Telephone: 0-2264-9090 Facsimile: 0-2264-0789
- Year of Service** : 2 Years (Signatory for the financial statements of the company for the fiscal years 2021 and 2022)

**Ms. Sumesa Tangyoosuk**

Partner

EY Office Limited

Certificated public accountant number 5238

- Education** : Master's degree in Accountancy, Thammasat University
Bachelor's degree in Accountancy, Thammasat University
- Experience in the last five years** : 2020 – Present: Assurance Partner, EY Office Limited
- Qualification** : Certified Public Accountant (Thailand), Auditor Approved by the office of The Securities and Exchange Commission of Thailand and The Stock Exchange of Thailand, Fellow of Thailand Federation of Accounting Professions (TFAC) and Working group of the Federation of Accounting Professions – ISAs Monitoring.
- Relationship with or Interest in (except for the audit service) the Company, Subsidiaries, Executives, Major Shareholders, or their Related Persons Capable of Undermining the Ability to Perform Duties Independently** : - None -
- Contact Details** : EY Office Limited
1875 One Bangkok Tower 3, Level 34 - 37, Rama 4 Road,
Kwang Lumpini, Khet Pathumwan Thailand, Bangkok 10330
Telephone: 0-2264-9090 Facsimile: 0-2264-0789
- Year of Service** : 3 Years (Signatory for the financial statements of the company for the fiscal years 2023, 2024 and 2025)



Ms. Sineenart Jirachaikh

Partner

EY Office Limited

Certificated public accountant number 6287

- Education** : Master's degree in Information Technology in Business,
Chulalongkorn University
Bachelor's degree in Accountancy, Chulalongkorn University
- Experience in the last five years** : 2016 – Present Assurance Partner, EY Office Limited
- Qualification** : Certified Public Accountant (Thailand), Auditor Approved by the
office of The Securities and Exchange Commission of Thailand
and The Stock Exchange of Thailand, Fellow of Thailand
Federation of Accounting Professions (TFAC).
- Relationship with or Interest in (except for the audit service) the Company, Subsidiaries, Executives, Major Shareholders, or their Related Persons Capable of Undermining the Ability to Perform Duties Independently** : - None -
- Contact Details** : EY Office Limited
1875 One Bangkok Tower 3, Level 34 - 37, Rama 4 Road,
Kwang Lumphini, Khet Pathumwan Thailand, Bangkok 10330
Telephone: 0-2264-9090 Facsimile: 0-2264-0789
- Year of Service** : - (Not being the signatory on the financial statements)

Profile of the independent director proposed as a proxy



Name : Mr. Dusit Chongsuttanamaanee
Present Position : Chairman of the Audit Committee
 Chairman of the Nomination and Remuneration Committee
 Independent Director

Age : 54 years old
Nationality : Thai
Address : 224/575 Bond Street Road, Bang-Phut Sub-District, Prakkret District, Nonthaburi 11120
Education : Master of Business Administration, Kasetsart University
 Bachelor of Engineering (Second Class Honor), Mahanakorn University of Technology
Training attended : Company Secretary Program (CSP) Class 74/2016
 Director Accreditation Program (DAP) Class 137/2017
Possession of DOD shares : - None - (0% of total issued shares)
Work Experiences : Present: Chairman of the Board/ Member of the Audit Committee/ Member of the Nomination and Remuneration Committee and Independent Director, 88(Thailand) Public Company Limited
 2015 – Present: Vice Chairman of the Board/ Chairman of the Audit Committee/ Chairman of the Nomination and Remuneration Committee and Independent Director, DOD Biotech Public Company Limited
 2008 – Present: Chairman of Executive Director, Siri Assets Company Limited
 2008 – Present: Chairman of Board Director, Kin Author Company Limited
 2005 – Present: Risk Management Director and Corporate Secretary, Pranda Jewelry Public Company Limited
Having a vested interest in the agenda items proposed at the 2026 Annual General Meeting (AGM) : No vested interest in any of the agenda items proposed

Provisions of the Articles of Association and law relating to Shareholders meetings

Chapter 4

Director and Their Power

Article 21. The election of the Company's directors shall be made by the Meeting of Shareholders, in accordance with the following rules and procedures:

- (1) Every shareholder shall have one (1) vote per one (1) share
- (2) Each shareholder must use all of their votes specified in (1) to elect one person or more to be the director(s) but may not divide his/her votes among several persons.
- (3) The persons who receive the highest votes in descending order shall be elected as directors equal to the number of directors to be elected on that occasion. In the event that the persons being elected in subsequent order have equal votes but their election would exceed the number of directors required to be elected in that meeting, the chairman of the meeting shall have a casting vote.

Article 22. At the Annual General Meeting of Shareholders in each year, not less than one-third (1/3) of the number of the directors in the Board of Directors shall retire by rotation. If the number of directors to retire by rotation cannot be divided into three (3) parts, the closest number to one-third (1/3) shall retire from directorship in the first year. In the second year following the Company's registration, the termination of members of Board of Directors shall be determined by drawing lots. In the subsequent years, the directors with longest period of directorship is required to leave the position. However, the directors who are retired by rotation may be re-elected to assume the directorship.

Article 23. Directors' bonus and remuneration are determined by the Meeting of Shareholders. The directors shall have the right to receive remuneration from the Company in the form of reward, meeting allowances, gratuity, bonus, or fringe benefit in accordance with the Company's Articles of Association, or the consideration of the Meeting of Shareholders, which may specifically determine the amount or determine the rules either from time to time or to be in full force and effect until the change and additionally receiving allowances and benefits according to the Company's Articles of Association.

The provision of the preceding paragraph shall not prejudice the rights of the staff and employees of the Company whom be elected as a director to receive remuneration, and benefits as an officer or employee of the Company.

The payment of remuneration according to the first and second paragraphs shall not be contrary to or inconsistent with the qualifications of independent directors as specified by the Securities and Exchange Act.

Article 28. The Meeting of Shareholders may pass a resolution to remove any director from office before the expiration of the term by a vote of not less than three-fourths (3/4) of the number of shareholders attending the meeting and entitled to vote and having a total of not less than one-half (1/2) of the shares held by the shareholders attending the meeting and entitled to vote.

Chapter 5

Meeting of Shareholder

Article 37. The Meeting of Shareholders shall be held at the location of the Company's head office or nearby provinces or elsewhere as determined by the Board of Directors

Article 38. The Board of Directors shall convene the Meeting of Shareholders at least once (1) a year. Such meetings are called the "General Meeting," which shall be held within four (4) months from the last day of the fiscal year of the Company. Meeting of Shareholders other than the aforesaid shall be called the "Extraordinary Meeting."

The Board of Directors may summon an Extraordinary Meeting whenever it deems appropriate or one or many shareholders holding shares in aggregate not less than ten (10) per cent of the total number of issued shares may at any time subscribe their names in a letter requesting the Board of Directors to call an extraordinary meeting, providing that they clearly state the reasons for such request in the said letter. In this case, the Board of Directors shall call the Meeting of Shareholders within forty-five (45) days from the date of receipt of such letter from the shareholders.

In the event that the Board of Directors does not hold a meeting under the period specified in the second paragraph. All shareholders who have subscribed their names together or other collective shareholders aggregated to the number of shares as required can call the meeting by themselves within forty-five days from the expiration of the period under the second paragraph. In this case, it shall be considered as a Meeting of Shareholders which the Board of Directors convenes. The Company is responsible for the necessary expenses incurred from arranging the meeting and the reasonable facilitation. In the event that the Meeting of Shareholders, which is a meeting of shareholders due to the shareholders under the third paragraph, at any time the number of shareholders attending the meeting is not a quorum as stipulated in Article 40, the shareholders

under the third paragraph must be jointly responsible for the expenses incurred from arranging that meeting for the Company.

Article 39. In summoning the Meeting of Shareholders, the Board of Directors shall prepare an invitation letter of the meeting specifying the venue, date, time, agenda and the matters to be submitted to the meeting together with appropriate details stating clearly whether they will be for acknowledgement, for approval or for consideration, including the opinions of the Board of Directors on the said matters and shall send the same to the shareholders and the Registrar for information not less than seven (7) days prior to the meeting. Publication of invitation of the meeting shall also be made in a newspaper for three (3) consecutive days no less than three (3) days prior to the meeting.

The Board of Directors or the assigned directors shall determine the date, time and venue of the Meeting of Shareholders. The venue to be used as the place for Meeting of Shareholders must be in the locality where the head office or branch office is located, or in other provinces or other venues as the Board of Directors deems appropriate.

Article 40. At the Meeting of Shareholders, there shall be shareholders and proxies (if any) attending the meeting at a number amounting to not less than twenty-five (25) persons or not less than one half of the total number of shareholders holding shares altogether amounting to not less than one-thirds (1/3) of the total number of issued shares to constitute a quorum.

In case after one (1) hour from the time fixed for the Meeting of Shareholders, the number of shareholder present is insufficient to form a quorum as specified, when the Meeting of Shareholders was convened at the request of shareholders, it shall be canceled. If such Meeting of Shareholders was not convened at the request of shareholders, a quorum for the latter meeting is not compulsory.

Article 41. At the Meeting of Shareholders, the shareholders may authorize other persons as proxies to attend and vote at the meeting on their behalf. The proxy must be made in writing and signed by the proxy grantor. It must be in accordance with the form specified by the Public Company Limited Registrar and at least has the following details:

- (1) The number of shares held by the proxy grantor
- (2) Name of the proxy
- (3) The time of the meeting that was authorized to attend the meeting and vote. The instrument appointing the proxy shall be submitted to the Chairman of the Board or a person entrusted by him at the meeting venue before the attendance of the proxy.

Article 42. In the Meeting of Shareholders, the Chairman of the Board shall preside over the meeting. If the Chairman is not present or is unable to perform the duty, and if there is a Vice-Chairman, the Vice-Chairman present at the meeting shall be the chairman of the meeting. If there is no Vice-Chairman or there is a Vice-Chairman but cannot perform his duties, the shareholders attending the meeting shall elect one of the shareholders amongst them to preside over the meeting.

Article 43. The chairman of the Meeting of Shareholders is responsible for controlling the meeting in compliance with the law and the Company's Articles of Association relating to the meeting. In this regard, the Meeting of Shareholders must be conducted in accordance with the order of the agenda specified in the meeting invitation. Unless the meeting has a resolution to change the order of the agenda by a vote of not less than two-thirds (2/3) of the number of shareholders attending the meeting.

When the meeting considers the matter in accordance with the agenda specified in the invitation to the meeting, shareholders with a total of not less than one-third (1/3) of the total number of shares sold may request that the meeting considers the matters other than those specified in the meeting invitation letter.

In the case that the meeting considers the matter according to the agenda specified in the meeting invitation letter, or the matter that the shareholders propose is not completed and need to postpone the consideration, the meeting is to determine the venue and time for the next meeting. The Board of Directors shall send an invitation of the meeting specifying the venue, date, time and agenda to shareholders not less than seven (7) days prior to the meeting. Publication of invitation of the meeting shall also be made in a newspaper for three (3) consecutive days no less than three (3) days prior to the meeting.

Article 44. In voting at the Meeting of Shareholders, every shareholder has one (1) vote per one (1) share. In the event that any shareholder has a special interest in any matter that the meeting has voted, that shareholder will not have the right to vote on that matter unless it is the vote for an election of directors.

Article 45. The resolutions of the Meeting of Shareholders shall be passed by the following votes:

- (1) In an ordinary circumstance, the majority vote of shareholders who attend the meeting and cast their votes.
- (2) In case of the tie vote, the chairman of the meeting shall have a casting vote.
- (3) In the following circumstances, a vote of not less than three-fourths (3/4) of the total number of votes of shareholders who attend the meeting and entitled to vote:
 - a) sale or transfer of the whole or important parts of the business of the Company to other persons

- b) purchase or acceptance of transfer of the business of other companies or private companies by the Company
- c) entering, amending or terminating of contracts with respect to the granting of a lease of the whole or important parts of the business of the Company,
- d) assignment of the management of the business of the Company to any other persons
- e) merging of the business with other persons with the purpose of profit and loss sharing
- f) amendment or alteration of the Company's Memorandum or Articles of Associations
- g) increase or decrease of the Company's capital
- h) Issuing Debenture
- i) amalgamation or dissolution of the Company
- j) any other matters as required by law

Article 46. Transactions to be conducted at the Annual General Meeting are as follows:

- (1) Reviewing the report of the Board of Directors covering the Company's business during the preceding year as proposed by the Board of Directors
- (2) Considering and approving the balance sheet and financial statement and the Company's profit and loss account at the end of the fiscal year of the Company
- (3) Considering the appropriation of profits and dividend payment
- (4) Considering and approving the election of new directors replacing of those retiring by rotation and determining the remuneration for directors
- (5) To consider the appointment of the auditor and determine the auditor's remuneration.
- (6) Other business

Chapter 8

Dividends and Reserves

Article 52 Dividends shall not be paid other than profits. In this case, the company still has accumulated losses.

It is forbidden to pay dividends. It is forbidden to declare dividends. In addition to the resolution of the shareholders' meeting Or the resolution of the board In the event of an interim dividend, the dividend payment shall be made to the shareholders. And to advertise the notice of dividend payment in one local newspaper for a period of three (3) consecutive days and arrange such dividend payment within one (1) month from the date of such resolution.

Article 53 The Board of Directors may pay interim dividends to shareholders from time to time. When it appears to the director that the company has a reasonable profit to do so And when the dividend has been paid, it shall be reported to the shareholders 'meeting at the next shareholders' meeting.

Article 54. Dividends shall be distributed according to the number of shares, each share equally, except in the case that the company issues preferred shares and determines that the preferred shares receive dividends different from ordinary shares. To allocate dividends as specified

Article 55 The company must allocate part of the annual net profit as reserve fund of not less than five (5) percent of the annual net profit. Deducted by the accumulated loss brought forward (if any) until the accumulated amount in this amount is not less than ten (10) percent of the registered capital. In addition to the aforementioned reserves The Board of Directors may propose to the shareholders' meeting to allocate other reserve funds. As seen to be beneficial in the operation of the company as well. When the company has been approved by the shareholders' meeting The company may transfer other reserves. Legal reserve and advance capital reserve, respectively to compensate the accumulated loss of the company

Article 56 In the event that the company has not sold the full amount of shares to be registered or the company has registered to increase its capital The company may pay dividends in whole or in part. By issuing new ordinary shares to the shareholders with the approval of the shareholders' meeting.

ปิดอากร
แสตมป์
20 บาท

สิ่งที่ส่งมาด้วย 6

หนังสือมอบฉันทะ แบบ ก.

Proxy Form A.

เขียน

Made At.....

วัน..... เดือน พ.ศ.....

Date..... Month..... Year.....

(1) ข้าพเจ้า..... สัญชาติ.....
I/We..... Nationality.....
สำนักงานตั้งอยู่เลขที่..... ถนน..... ตำบล/แขวง.....
Located at No..... Road..... Sub-District.....
อำเภอ / เขต..... จังหวัด..... รหัสไปรษณีย์.....
District..... Province..... Post Code.....

(2) เป็นผู้ถือหุ้นของ บริษัท ดีโอดี ไบโอเทค จำกัด (มหาชน)

Being a shareholder of DOD Biotech PCL

โดยมีหุ้นจำนวนทั้งสิ้น.....หุ้น และออกเสียงคะแนนได้เท่ากับ.....เสียง ดังนี้
Holdingshares Which are entitled to cast.....Vote as follow
 หุ้นสามัญหุ้น และออกเสียงลงคะแนนได้เท่ากับ.....เสียง
Ordinary share.....shares In total which are entitled to cast.....Votes
 หุ้นบุริมสิทธิ.....หุ้น และออกเสียงลงคะแนนได้เท่ากับ.....เสียง
Preferred share.....shares In total which are entitled to cast.....Votes

(3) ขอมอบฉันทะให้ / I/We wish to appoint

(1) ชื่อ..... อายุ.....ปี
Name..... Age.....Years
สำนักงานตั้งอยู่เลขที่..... ถนน..... ตำบล/แขวง.....
Located at No..... Road..... Sub-District.....
อำเภอ / เขต..... จังหวัด..... รหัสไปรษณีย์.....
District..... Province..... Post Code.....

หรือมอบฉันทะให้กรรมการอิสระ / Or Appoint Independent Director

<input type="checkbox"/> (2) ชื่อ	นายดุสิต จงสุทธนามณี			อายุ	54	ปี
Name	MR. DUSIT CHONGSUTTHANAMANEI			Age	54	Years
สำนักงานตั้งอยู่เลขที่	224/575	ถนน	บอนด์สตรีท	ตำบล/แขวง	บางพูด	
Located at	No. 224/575	Road	Bond Street	Sub-District	Bang-Phut	
อำเภอ / เขต	ปากเกร็ด	จังหวัด	นนทบุรี	รหัสไปรษณีย์	11120	
District	Prakkret	Province	Nonthaburi	Post Code	11120	

คนหนึ่งคนใดเพียงคนเดียวเป็นผู้แทนของข้าพเจ้า เพื่อเข้าร่วมประชุมและออกเสียงลงคะแนนแทนข้าพเจ้า ในการประชุมสามัญผู้ถือหุ้น ประจำปี 2569 ในวันศุกร์ ที่ 10 เมษายน 2569 เวลา 14.00 น. ด้วยวิธีการผ่านสื่ออิเล็กทรอนิกส์รูปแบบเดียวเท่านั้น โดยถ่ายทอดจากห้องประชุมสำนักงานใหญ่ บริษัท ดีโอที ไบโอเทค จำกัด (มหาชน) เลขที่ 111 หมู่ที่ 2 ตำบลท่าจีน อำเภอเมืองสมุทรสาคร จังหวัดสมุทรสาคร 74000 หรือที่จะพึงเลื่อนไปในวัน เวลา และสถานที่อื่นด้วย

any one of them as my/our proxy to attend and vote on my/our behalf at the 2026 Annual General Meeting of Shareholders to be held on Friday, 10 April 2026 at 2:00 p.m. via electronic media by relaying from the meeting room, head office, DOD Biotech Public Company Limited, No. 111 Moo 2, Tha Chin Sub-district, Samut Sakhon District, Samut Sakhon Province 74000 Thailand or such other date, time and place as may be adjourned.

กิจการใดที่ผู้รับมอบฉันทะกระทำให้ในการประชุม ให้ถือเสมือนว่าข้าพเจ้าได้กระทำเองทุกประการ

Any act or performance caused by the Proxy at the above meeting shall be deemed as my/our acts and performance in all respects.

ลงชื่อ/ Signature.....ผู้มอบฉันทะ/ The Grantor
 (.....)

ลงชื่อ/ Signature.....ผู้รับมอบฉันทะ/ The Proxy
 (.....)

ลงชื่อ/ Signature.....ผู้รับมอบฉันทะ/ The Proxy
 (.....)

ลงชื่อ/ Signature.....ผู้รับมอบฉันทะ/ The Proxy
 (.....)

หมายเหตุ/ Remark:

ผู้ถือหุ้นที่มอบฉันทะจะต้องมอบฉันทะให้ผู้รับมอบฉันทะเพียงรายเดียวเป็นผู้เข้าประชุมและออกเสียงลงคะแนนไม่สามารถแบ่งแยกจำนวนหุ้นให้ผู้รับมอบฉันทะหลายคนเพื่อแยกการลงคะแนนเสียงได้ A Shareholder may grant a proxy to only one person.

The number of shares held by a shareholder may not be divided into several portions and granted to more than one proxy in order to divide the votes.

ปิดอากร
แสตมป์
20 บาท

สิ่งที่ส่งมาด้วย 6

หนังสือมอบฉันทะ แบบ ข.

Proxy Form B.

เขียน

Made At.....

วัน..... เดือน พ.ศ.....

Date..... Month..... Year.....

(1) ข้าพเจ้า..... สัญชาติ.....
I/We..... Nationality.....
สำนักงานตั้งอยู่เลขที่..... ถนน..... ตำบล/แขวง.....
Located at No..... Road..... Sub-District.....
อำเภอ / เขต..... จังหวัด..... รหัสไปรษณีย์.....
District..... Province..... Post Code.....

เป็นผู้ถือหุ้นของ บริษัท ดีโอที ไบโอเทค จำกัด (มหาชน)

Being a shareholder of DOD Biotech PCL

โดยมีหุ้นจำนวนทั้งสิ้น.....หุ้น และออกเสียงคะแนนได้เท่ากับ.....เสียง ดังนี้
Holdingshares Which are entitled to cast.....Vote as follow
 หุ้นสามัญหุ้น และออกเสียงลงคะแนนได้เท่ากับ.....เสียง
Ordinary share.....shares In total which are entitled to cast.....Votes
 หุ้นบุริมสิทธิ.....หุ้น และออกเสียงลงคะแนนได้เท่ากับ.....เสียง
Preferred share.....shares In total which are entitled to cast.....Votes

(2) ขอมอบฉันทะให้ / Authorize one of the following persons:

(1) ชื่อ..... อายุ.....ปี
Name..... Age.....Years
สำนักงานตั้งอยู่เลขที่..... ถนน..... ตำบล/แขวง.....
Located at No..... Road..... Sub-District.....
อำเภอ / เขต..... จังหวัด..... รหัสไปรษณีย์.....
District..... Province..... Post Code.....

หรือมอบฉันทะให้กรรมการอิสระ / Or Appoint Independent Director

<input type="checkbox"/> (2) ชื่อ	นายดุสิต จงสุทธนามณี			อายุ	54	ปี
Name	MR. DUSIT CHONGSUTTHANAMANE			Age	54	Years
สำนักงานตั้งอยู่เลขที่	224/575	ถนน	บอนด์สตรีท	ตำบล/แขวง	บางพูด	
Located at	No. 224/575	Road	Bond Street	Sub-District	Bang-Phut	
อำเภอ / เขต	ปากเกร็ด	จังหวัด	นนทบุรี	รหัสไปรษณีย์	11120	
District	Prakkret	Province	Nonthaburi	Post Code	11120	

คนหนึ่งคนใดเพียงคนเดียวเป็นผู้แทนของข้าพเจ้า เพื่อเข้าร่วมประชุมและออกเสียงลงคะแนนแทนข้าพเจ้า ในการประชุมสามัญผู้ถือหุ้น ประจำปี 2569 ในวันศุกร์ ที่ 10 เมษายน 2569 เวลา 14.00 น. ด้วยวิธีการผ่านสื่ออิเล็กทรอนิกส์รูปแบบเดียวเท่านั้น โดยถ่ายทอดจากห้องประชุมสำนักงานใหญ่ บริษัท ดีไอดี ไบโอเทค จำกัด (มหาชน) เลขที่ 111 หมู่ที่ 2 ตำบลท่าจีน อำเภอเมืองสมุทรสาคร จังหวัดสมุทรสาคร 74000 หรือที่จะพึงเลื่อนไปในวัน เวลา และสถานที่อื่นด้วย

any one of them as my/our proxy to attend and vote on my/our behalf at the 2026 Annual General Meeting of Shareholders to be held on Friday, 10 April 2026 at 2:00 p.m. via electronic media by relaying from the meeting room, head office, DOD Biotech Public Company Limited, No. 111 Moo 2, Tha Chin Sub-district, Samut Sakhon District, Samut Sakhon Province 74000 Thailand or such other date, time and place as may be adjourned.

(3) ข้าพเจ้าขอมอบฉันทะให้ผู้รับมอบฉันทะเข้าร่วมประชุมและออกเสียงลงคะแนนในครั้งนี้ ดังนี้

I/We hereby authorize the proxy to attend and vote on my/our behalf in this meeting as follows:

- มอบฉันทะตามจำนวนหุ้นทั้งหมดที่ถือและมีสิทธิออกเสียงลงคะแนนได้

to vote with the total number of shares held by me/us to which I/we am/are entitled.

- มอบฉันทะบางส่วน คือ

หุ้นสามัญ	หุ้น และออกเสียงลงคะแนนได้เท่ากับ.....	เสียง
Ordinary share	shares and voting right is	votes
หุ้นบุริมสิทธิ.....	หุ้น และออกเสียงลงคะแนนได้เท่ากับ.....	เสียง
Preferred share	shares and voting right is	votes
รวมสิทธิออกเสียงลงคะแนนได้ทั้งหมด.....		เสียง
Total number of voting right is		vote

(4) ข้าพเจ้าขอมอบฉันทะให้ผู้รับมอบฉันทะออกเสียงลงคะแนนแทนข้าพเจ้าในการประชุมครั้งนี้ ดังนี้

I/We authorize my/our Proxy to cast the vote on my/our behalf at the above meeting in the following manners:

วาระที่ 1 พิจารณารับทราบผลการดำเนินงานของบริษัท ประจำปี 2568

Agenda No.1 To acknowledge the directors' report on the Company's performance for the year 2025.
 - ไม่มีการลงมติ / No casting of votes in this agenda.

วาระที่ 2 พิจารณานุมัติงบการเงินสำหรับปี สิ้นสุดวันที่ 31 ธันวาคม 2568

Agenda No.2 To consider approving the Company's audited the financial statements for the year ended December 31, 2025.

- (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

The proxy is entitled to cast the votes on my/our behalf at its own discretion

- (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

The proxy must cast the votes in accordance with my following instructions

เห็นด้วย.....เสียง ไม่เห็นด้วย.....เสียง งดออกเสียง.....เสียง
Approve votes Disapprove votes Abstain votes

วาระที่ 3

พิจารณาอนุมัติการจัดสรรกำไรสุทธิเป็นทุนสำรองตามกฎหมายและการจ่ายเงินปันผล สำหรับผลการดำเนินงาน ปี 2568

Agenda No.3

To consider and approve the allocation of net profit as legal reserve and the dividend payment for the 2025 operating results.

- (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

The proxy is entitled to cast the votes on my/our behalf at its own discretion

- (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

The proxy must cast the votes in accordance with my following instructions

เห็นด้วย.....เสียง ไม่เห็นด้วย.....เสียง งดออกเสียง.....เสียง
Approve votes Disapprove votes Abstain votes

วาระที่ 4

พิจารณาอนุมัติการแก้ไขเพิ่มเติมวัตถุประสงค์ของบริษัท และแก้ไขเพิ่มเติมหนังสือบริคณห์สนธิ ข้อ 3. เพื่อให้สอดคล้องกับการแก้ไขเพิ่มเติมวัตถุประสงค์ของบริษัท

Agenda No.4

To consider and approve the amendment of the Company's Objectives and the amendment of the Memorandum of Association, Clause 3, to be consistent with the amendment of the Company's Objectives.

- (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

The proxy is entitled to cast the votes on my/our behalf at its own discretion

- (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

The proxy must cast the votes in accordance with my following instructions

เห็นด้วย.....เสียง ไม่เห็นด้วย.....เสียง งดออกเสียง.....เสียง
Approve votes Disapprove votes Abstain votes

วาระที่ 5

พิจารณาลดทุนจดทะเบียนที่ยังไม่ได้ชำระ และแก้ไขเพิ่มเติมหนังสือบริคณห์สนธิ ข้อ 4. เพื่อให้สอดคล้องกับการลดทุนจดทะเบียนของบริษัท

Agenda No.5

To consider the reduction of the unissued registered capital and the amendment of the Memorandum of Association, Clause 4, to be consistent with the reduction of the Company's registered capital.

- (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

The proxy is entitled to cast the votes on my/our behalf at its own discretion

- (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

The proxy must cast the votes in accordance with my following instructions

เห็นด้วย.....เสียง ไม่เห็นด้วย.....เสียง งดออกเสียง.....เสียง
Approve votes Disapprove votes Abstain votes

วาระที่ 6 พิจารณานุมัติการเสนอชื่อกรรมการที่ครบกำหนดออกตามวาระกลับเข้าดำรงตำแหน่งกรรมการอีกวาระหนึ่ง

Agenda No.6 To consider and approve the appointment of the directors those retired by rotation to re-elect the aforementioned to be the Company's director for another term.

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

The proxy is entitled to cast the votes on my/our behalf at its own discretion

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

The proxy must cast the votes in accordance with my following instructions

การแต่งตั้งกรรมการเป็นรายคณะ

Appointment of all directors

เห็นด้วย.....เสียง ไม่เห็นด้วย.....เสียง งดออกเสียง.....เสียง
Approve votes Disapprove votes Abstain votes

การแต่งตั้งกรรมการเป็นรายบุคคล

Appointment of any director(s)

1) ชื่อกรรมการ **นางอาภาภรณ์ โกศลกุล**

Name of Director: **Mrs. Apaporn Kosolkul**

เห็นด้วย.....เสียง ไม่เห็นด้วย.....เสียง งดออกเสียง.....เสียง
Approve vote Disapprove votes Abstain votes

2) ชื่อกรรมการ **นายพงษ์เทพ ธิฐาพันธ์**

Name of Director: **Mr. Pongtep Thithapand**

เห็นด้วย.....เสียง ไม่เห็นด้วย.....เสียง งดออกเสียง.....เสียง
Approve vote Disapprove votes Abstain votes

วาระที่ 7 พิจารณานุมัติกำหนดค่าตอบแทนคณะกรรมการประจำปี 2569

Agenda No.7 To approve the fixing of the director's remuneration for the year 2026

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

The proxy is entitled to cast the votes on my/our behalf at its own discretion

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

The proxy must cast the votes in accordance with my following instructions

เห็นด้วย.....เสียง ไม่เห็นด้วย.....เสียง งดออกเสียง.....เสียง
Approve votes Disapprove votes Abstain votes

วาระที่ 8 พิจารณานุมัติแต่งตั้งผู้สอบบัญชีและกำหนดค่าตอบแทนผู้สอบบัญชีประจำปี 2569

Agenda No.8 To approve the appointment of the auditors and fixing the audit fee for the year 2026

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

The proxy is entitled to cast the votes on my/our behalf at its own discretion

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

The proxy must cast the votes in accordance with my following instructions

เห็นด้วย.....เสียง ไม่เห็นด้วย.....เสียง งดออกเสียง.....เสียง
Approve votes Disapprove votes Abstain votes

วาระที่ 9 พิจารณาเรื่องอื่นๆ (ถ้ามี)
Agenda No.9 Other business (if any)

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

The proxy is entitled to cast the votes on my/our behalf at its own discretion

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

The proxy must cast the votes in accordance with my following instructions

เห็นด้วย.....เสียง ไม่เห็นด้วย.....เสียง งดออกเสียง.....เสียง
Approve votes Disapprove votes Abstain votes

(5) การลงคะแนนเสียงของผู้รับมอบฉันทะในวาระใดที่ไม่เป็นไปตามที่ระบุไว้ในหนังสือมอบฉันทะนี้ให้ถือว่าการลงคะแนนเสียงนั้นไม่ถูกต้องและไม่ถือเป็นการลงคะแนนเสียงของผู้ถือหุ้น

Any agenda voting of the Proxy which is not complied with my intention specified herein shall not be deemed as my/our votes as a shareholder.

(6) ในกรณีที่ข้าพเจ้าไม่ได้ระบุความประสงค์ในการออกเสียงลงคะแนนในวาระใดไว้หรือระบุไว้ไม่ชัดเจนหรือในกรณีที่ประชุมมีการพิจารณาหรือ ลงมติในเรื่องใดนอกเหนือจากเรื่องที่ระบุไว้ข้างต้น รวมถึงกรณีที่มีการแก้ไขเปลี่ยนแปลงหรือเพิ่มเติมข้อเท็จจริงประการใดให้ผู้รับมอบฉันทะ มีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

In case I/we do not specify or clearly specify my/our intention to vote in any agenda, or there is any agenda considered in the meeting other than those specified above, or if there is any change or amendment to any fact, the Proxy shall be authorized to consider and vote on my/our behalf as the Proxy deems appropriate.

กิจการใดที่ผู้รับมอบฉันทะได้กระทำไปในการประชุม เว้นแต่กรณีที่ผู้รับมอบฉันทะไม่ออกเสียงตามที่ข้าพเจ้าระบุในหนังสือมอบฉันทะให้ถือเสมือนว่าข้าพเจ้าได้กระทำเองทุกประการ

Any action taken by the Proxy at the meeting shall, unless the Proxy cast the votes not in compliance with my/our intention specified herein, be deemed as being done by me/us in all respects.

ผู้มอบฉันทะ

The Grantor

ผู้รับมอบฉันทะ

The Proxy

ลงชื่อ.....

Signature

ลงชื่อ

Signature

หมายเหตุ

Remark;

1. ผู้ถือหุ้นที่มอบฉันทะจะต้องมอบฉันทะให้ผู้รับมอบฉันทะเพียงรายเดียวเป็นผู้เข้าประชุมและออกเสียงลงคะแนนไม่สามารถแบ่งแยกจำนวนหุ้นให้ผู้รับมอบฉันทะหลายคนเพื่อแยกการลงคะแนนเสียงได้

A shareholder appointing a proxy must authorize only one proxy to attend the meeting and cast the votes on their behalf. The number of shares held by such shareholder may not be split among multiple proxies to separate the votes.

2. วาระเลือกตั้งกรรมการสามารถเลือกตั้งกรรมการทั้งชุดหรือเลือกตั้งกรรมการเป็นรายบุคคล

In the agenda of appointment of directors, the directors may be elected as a whole slate or on an individual basis.

3. ในกรณีที่มีวาระที่จะพิจารณาในการประชุมมากกว่าวาระที่ระบุไว้ข้างต้น ผู้มอบฉันทะสามารถระบุเพิ่มเติมได้ในใบประจำต่อแบบหนังสือมอบฉันทะ (แบบ ข.) ตามแนบ

In the event that there are more agendas to be considered than those specified above, the proxy grantor may specify such additional agendas in the Annex to Proxy Form B as attached.

ใบประจำต่อแบบหนังสือมอบฉันทะ (แบบ ข.)

การมอบฉันทะในฐานะเป็นผู้ถือหุ้นของบริษัท ดีโอดี ไบโอเทค จำกัด (มหาชน)

ในการประชุมสามัญผู้ถือหุ้น ประจำปี 2569

ในวันศุกร์ที่ 10 เมษายน 2569 เวลา 14.00 น. ผ่านสื่ออิเล็กทรอนิกส์ (E-AGM)

Attachment to Proxy Form (Form B)

Proxy grant for the shareholder of DOD Biotech Public Company Limited

At the 2026 Annual General Meeting of Shareholders

on Friday, April 10, 2026, at 2:00 p.m. via Electronic Media (E-AGM)

วาระที่ เรื่อง.....

Agenda No..... Subject.....

 (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

The proxy is entitled to cast the votes on my/our behalf at its own discretion

 (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

The proxy must cast the votes in accordance with my following instructions

 เห็นด้วย.....เสียง ไม่เห็นด้วย.....เสียง งดออกเสียง.....เสียง

Approve votes Disapprove votes Abstain votes

วาระที่ เรื่อง.....

Agenda No..... Subject.....

 (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

The proxy is entitled to cast the votes on my/our behalf at its own discretion

 (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

The proxy must cast the votes in accordance with my following instructions

 เห็นด้วย.....เสียง ไม่เห็นด้วย.....เสียง งดออกเสียง.....เสียง

Approve votes Disapprove votes Abstain votes

วาระที่ เรื่อง.....

Agenda No..... Subject.....

 (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

The proxy is entitled to cast the votes on my/our behalf at its own discretion

 (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

The proxy must cast the votes in accordance with my following instructions

 เห็นด้วย.....เสียง ไม่เห็นด้วย.....เสียง งดออกเสียง.....เสียง

Approve votes Disapprove votes Abstain votes

วาระที่ พิจารณานุมัติการเสนอชื่อกรรมการ

Agenda No..... To consider and approve the appointment of the directors

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร
The proxy is entitled to cast the votes on my/our behalf at its own discretion

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้
The proxy must cast the votes in accordance with my following instructions

การแต่งตั้งกรรมการเป็นรายคณะ

Appointment of all directors

เห็นด้วย.....เสียง ไม่เห็นด้วย.....เสียง งออกเสียง.....เสียง
Approve votes Disapprove votes Abstain votes

การแต่งตั้งกรรมการเป็นรายบุคคล

Appointment of any director(s)

1) ชื่อกรรมการ.....

Name of Director:

เห็นด้วย.....เสียง ไม่เห็นด้วย.....เสียง งออกเสียง.....เสียง
Approve vote Disapprove votes Abstain votes

2) ชื่อกรรมการ.....

Name of Director:

เห็นด้วย.....เสียง ไม่เห็นด้วย.....เสียง งออกเสียง.....เสียง
Approve vote Disapprove votes Abstain votes

3) ชื่อกรรมการ.....

Name of Director:

เห็นด้วย.....เสียง ไม่เห็นด้วย.....เสียง งออกเสียง.....เสียง
Approve vote Disapprove votes Abstain votes

ข้าพเจ้าขอรับรองว่ารายการในใบประจำต่อแบบหนังสือมอบฉันทะ ถูกต้องบริบูรณ์และเป็นความจริงทุกประการ

I hereby certify that the statements in this Supplemental Proxy Form are correct, complete, and true in all respects.

ผู้มอบฉันทะ

The Grantor

ผู้รับมอบฉันทะ

The Proxy

ลงชื่อ.....

Signature

ลงชื่อ

Signature

ปิดอากร
แสตมป์
20 บาท

สิ่งที่ส่งมาด้วย 6

หนังสือมอบฉันทะ แบบ ค.

Proxy Form C.

เขียน

Made At.....

วัน..... เดือน พ.ศ.....

Date..... Month..... Year.....

(1) ข้าพเจ้า..... สัญชาติ.....

I/We..... Nationality.....

สำนักงานตั้งอยู่เลขที่..... ถนน..... สำนักงานตั้งอยู่เลขที่.....

Located at No..... Road..... Located at No.....

อำเภอ / เขต..... จังหวัด..... อำเภอ / เขต.....

District..... Province..... District.....

ในฐานะผู้ประกอบธุรกิจเป็นผู้รับฝากและดูแลหุ้น (Custodian) ให้กับ.....

As a custodian of.....

เป็นผู้ถือหุ้นของ บริษัท ดีโอดี ไบโอเทค จำกัด (มหาชน)

Being a shareholder of DOD Biotech PCL

โดยมีหุ้นจำนวนทั้งสิ้น.....หุ้น และออกเสียงคะแนนได้เท่ากับ.....เสียง ดังนี้

Holdingshares Which are entitled to cast.....Vote as follow

 หุ้นสามัญหุ้น และออกเสียงลงคะแนนได้เท่ากับ.....เสียง

Ordinary share.....shares In total which are entitled to cast.....Votes

 หุ้นบุริมสิทธิ.....หุ้น และออกเสียงลงคะแนนได้เท่ากับ.....เสียง

Preferred share.....shares In total which are entitled to cast.....Votes

(2) ขอมอบฉันทะให้ / Authorize one of the following persons:

 (1) ชื่อ.....อายุ.....ปี

Name..... Age.....Years

สำนักงานตั้งอยู่เลขที่..... ถนน..... ตำบล/แขวง.....

Located at No..... Road..... Sub-District.....

อำเภอ / เขต..... จังหวัด..... รหัสไปรษณีย์.....

District..... Province..... Post Code.....

หรือมอบฉันทะให้กรรมการอิสระ / Or Appoint Independent Director

<input type="checkbox"/> (2) ชื่อ	นายดุสิต จงสุทธนามณี			อายุ	54	ปี
Name	MR. DUSIT CHONGSUTTHANAMANE			Age	54	Years
สำนักงานตั้งอยู่เลขที่	224/575	ถนน	บอนด์สตรีท	สำนักงานตั้งอยู่เลขที่	224/575	
Located at	No. 224/575	Road	Bond Street	Located at	No. 224/575	
อำเภอ / เขต	ปากเกร็ด	จังหวัด	นนทบุรี	อำเภอ / เขต	ปากเกร็ด	
District	Prakkret	Province	Nonthaburi	District	Prakkret	

คนหนึ่งคนใดเพียงคนเดียวเป็นผู้แทนของข้าพเจ้า เพื่อเข้าร่วมประชุมและออกเสียงลงคะแนนแทนข้าพเจ้า ในการประชุมสามัญผู้ถือหุ้น ประจำปี 2569 ในวันศุกร์ ที่ 10 เมษายน 2569 เวลา 14.00 น. ด้วยวิธีการผ่านสื่ออิเล็กทรอนิกส์รูปแบบเดียวเท่านั้น โดยถ่ายทอดจากห้องประชุมสำนักงานใหญ่ บริษัท ดีไอที ไบโอเทค จำกัด (มหาชน) เลขที่ 111 หมู่ที่ 2 ตำบลท่าจีน อำเภอเมืองสมุทรสาคร จังหวัดสมุทรสาคร 74000 หรือที่จะพึงเลื่อนไปในวัน เวลา และสถานที่อื่นด้วย

any one of them as my/our proxy to attend and vote on my/our behalf at the 2026 Annual General Meeting of Shareholders to be held on Friday, 10 April 2026 at 2:00 p.m. via electronic media by relaying from the meeting room, head office, DOD Biotech Public Company Limited, No. 111 Moo 2, Tha Chin Sub-district, Samut Sakhon District, Samut Sakhon Province 74000 Thailand or such other date, time and place as may be adjourned.

(3) ข้าพเจ้าขอมอบฉันทะให้ผู้รับมอบฉันทะเข้าร่วมประชุมและออกเสียงลงคะแนนในครั้งนี้ ดังนี้

I/We hereby authorize the proxy to attend and vote on my/our behalf in this meeting as follows:

- มอบฉันทะตามจำนวนหุ้นทั้งหมดที่ถือและมีสิทธิออกเสียงลงคะแนนได้

to vote with the total number of shares held by me/us to which I/we am/are entitled.

- มอบฉันทะบางส่วน คือ

หุ้นสามัญ	หุ้น และออกเสียงลงคะแนนได้เท่ากับ.....	เสียง
Ordinary share	shares and voting right is	votes
หุ้นบุริมสิทธิ.....	หุ้น และออกเสียงลงคะแนนได้เท่ากับ.....	เสียง
Preferred share	shares and voting right is	votes
รวมสิทธิออกเสียงลงคะแนนได้ทั้งหมด.....		เสียง
Total number of voting right is		votes

(4) ข้าพเจ้าขอมอบฉันทะให้ผู้รับมอบฉันทะออกเสียงลงคะแนนแทนข้าพเจ้าในการประชุมครั้งนี้ ดังนี้

I/We authorize my/our Proxy to cast the vote on my/our behalf at the above meeting in the following manners:

วาระที่ 1 พิจารณารับทราบผลการดำเนินงานของบริษัท ประจำปี 2568

Agenda No.1 To acknowledge the directors' report on the Company's performance for the year 2025.
 - ไม่มีการลงมติ / No casting of votes in this agenda.

วาระที่ 2 พิจารณานุมัติงบการเงินสำหรับปี สิ้นสุดวันที่ 31 ธันวาคม 2568

Agenda No.2 To consider approving the Company's audited the financial statements for the year ended December 31, 2025.

- (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

The proxy is entitled to cast the votes on my/our behalf at its own discretion

- (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

The proxy must cast the votes in accordance with my following instructions

เห็นด้วย.....เสียง ไม่เห็นด้วย.....เสียง งดออกเสียง.....เสียง
Approve votes Disapprove votes Abstain votes

วาระที่ 3

พิจารณาอนุมัติการจัดสรรกำไรสุทธิเป็นทุนสำรองตามกฎหมายและการจ่ายเงินปันผล สำหรับผลการดำเนินงาน ปี 2568

Agenda No.3

To consider and approve the allocation of net profit as legal reserve and the dividend payment for the 2025 operating results.

- (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

The proxy is entitled to cast the votes on my/our behalf at its own discretion

- (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

The proxy must cast the votes in accordance with my following instructions

เห็นด้วย.....เสียง ไม่เห็นด้วย.....เสียง งดออกเสียง.....เสียง
Approve votes Disapprove votes Abstain votes

วาระที่ 4

พิจารณาอนุมัติการแก้ไขเพิ่มเติมวัตถุประสงค์ของบริษัท และแก้ไขเพิ่มเติมหนังสือบริคณห์สนธิ ข้อ 3. เพื่อให้สอดคล้องกับการแก้ไขเพิ่มเติมวัตถุประสงค์ของบริษัท

Agenda No.4

To consider and approve the amendment of the Company's Objectives and the amendment of the Memorandum of Association, Clause 3, to be consistent with the amendment of the Company's Objectives.

- (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

The proxy is entitled to cast the votes on my/our behalf at its own discretion

- (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

The proxy must cast the votes in accordance with my following instructions

เห็นด้วย.....เสียง ไม่เห็นด้วย.....เสียง งดออกเสียง.....เสียง
Approve votes Disapprove votes Abstain votes

วาระที่ 5

พิจารณาลดทุนจดทะเบียนที่ยังไม่ได้ชำระ และแก้ไขเพิ่มเติมหนังสือบริคณห์สนธิ ข้อ 4. เพื่อให้สอดคล้องกับการลดทุนจดทะเบียนของบริษัท

Agenda No.5

To consider the reduction of the unissued registered capital and the amendment of the Memorandum of Association, Clause 4, to be consistent with the reduction of the Company's registered capital.

- (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

The proxy is entitled to cast the votes on my/our behalf at its own discretion

- (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

The proxy must cast the votes in accordance with my following instructions

เห็นด้วย.....เสียง ไม่เห็นด้วย.....เสียง งดออกเสียง.....เสียง
Approve votes Disapprove votes Abstain votes

วาระที่ 6 พิจารณานุมัติการเสนอชื่อกรรมการที่ครบกำหนดออกตามวาระกลับเข้าดำรงตำแหน่งกรรมการอีกวาระหนึ่ง

Agenda No.6 To consider and approve the appointment of the directors those retired by rotation to re-elect the aforementioned to be the Company's director for another term.

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

The proxy is entitled to cast the votes on my/our behalf at its own discretion

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

The proxy must cast the votes in accordance with my following instructions

การแต่งตั้งกรรมการเป็นรายคณะ

เห็นด้วย.....เสียง ไม่เห็นด้วย.....เสียง งออกเสียง.....เสียง
Approve votes Disapprove votes Abstain votes

การแต่งตั้งกรรมการเป็นรายบุคคล

Appointment of any director(s)

1) ชื่อกรรมการ **นางอาภาภรณ์ โกศลกุล**

Name of Director: **Mrs. Apaporn Kosolkul**

เห็นด้วย.....เสียง ไม่เห็นด้วย.....เสียง งออกเสียง.....เสียง
Approve vote Disapprove votes Abstain votes

2) ชื่อกรรมการ **นายพงษ์เทพ ธิฐาพันธ์**

Name of Director: **Mr. Pongtep Thithapand**

เห็นด้วย.....เสียง ไม่เห็นด้วย.....เสียง งออกเสียง.....เสียง
Approve vote Disapprove votes Abstain votes

วาระที่ 7 พิจารณานุมัติกำหนดค่าตอบแทนคณะกรรมการประจำปี 2569

Agenda No.7 To approve the fixing of the director's remuneration for the year 2026

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

The proxy is entitled to cast the votes on my/our behalf at its own discretion

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

The proxy must cast the votes in accordance with my following instructions

เห็นด้วย.....เสียง ไม่เห็นด้วย.....เสียง งออกเสียง.....เสียง
Approve votes Disapprove votes Abstain votes

วาระที่ 8 พิจารณานุมัติแต่งตั้งผู้สอบบัญชีและกำหนดค่าตอบแทนผู้สอบบัญชีประจำปี 2569

Agenda No.8 To approve the appointment of the auditors and fixing the audit fee for the year 2026

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

The proxy is entitled to cast the votes on my/our behalf at its own discretion

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

The proxy must cast the votes in accordance with my following instructions

เห็นด้วย.....เสียง ไม่เห็นด้วย.....เสียง งออกเสียง.....เสียง
Approve votes Disapprove votes Abstain votes

วาระที่ 9 พิจารณาเรื่องอื่นๆ (ถ้ามี)

Agenda No.9 Other business (if any)

 (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

The proxy is entitled to cast the votes on my/our behalf at its own discretion

 (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

The proxy must cast the votes in accordance with my following instructions

 เห็นด้วย.....เสียง ไม่เห็นด้วย.....เสียง งดออกเสียง.....เสียง
Approve votes Disapprove votes Abstain votes

(5) การลงคะแนนเสียงของผู้รับมอบฉันทะในวาระใดที่ไม่เป็นไปตามที่ระบุไว้ในหนังสือมอบฉันทะนี้ให้ถือว่าการลงคะแนนเสียงนั้นไม่ถูกต้องและไม่ถือเป็นการลงคะแนนเสียงของผู้ถือหุ้น

Any agenda voting of the Proxy which is not complied with my intention specified herein shall not be deemed as my/our votes as a shareholder.

(6) ในกรณีที่ข้าพเจ้าไม่ได้ระบุความประสงค์ในการออกเสียงลงคะแนนในวาระใดไว้หรือระบุไว้ไม่ชัดเจนหรือในกรณีที่ประชุมมีการพิจารณาหรือ ลงมติในเรื่องใดนอกเหนือจากเรื่องที่ระบุไว้ข้างต้น รวมถึงกรณีที่มีการแก้ไขเปลี่ยนแปลงหรือเพิ่มเติมข้อเท็จจริงประการใดให้ผู้รับมอบฉันทะ มีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

In case I/we do not specify or clearly specify my/our intention to vote in any agenda, or there is any agenda considered in the meeting other than those specified above, or if there is any change or amendment to any fact, the Proxy shall be authorized to consider and vote on my/our behalf as the Proxy deems appropriate.

กิจการใดที่ผู้รับมอบฉันทะได้กระทำไปในการประชุม เว้นแต่กรณีที่ผู้รับมอบฉันทะไม่ออกเสียงตามที่ข้าพเจ้าระบุในหนังสือมอบฉันทะให้ถือเสมือนว่าข้าพเจ้าได้กระทำเองทุกประการ

Any action taken by the Proxy at the meeting shall, unless the Proxy cast the votes not in compliance with my/our intention specified herein, be deemed as being done by me/us in all respects.

ผู้มอบฉันทะ
The Grantorผู้รับมอบฉันทะ
The Proxyลงชื่อ.....
Signature

ลงชื่อ

Signature

หมายเหตุ

Remark;

1. ผู้ถือหุ้นที่มอบฉันทะจะต้องมอบฉันทะให้ผู้รับมอบฉันทะเพียงรายเดียวเป็นผู้เข้าประชุมและออกเสียงลงคะแนนไม่สามารถแบ่งแยกจำนวนหุ้นให้ผู้รับมอบฉันทะหลายคนเพื่อแยกการลงคะแนนเสียงได้

A shareholder appointing a proxy must authorize only one proxy to attend the meeting and cast the votes on their behalf. The number of shares held by such shareholder may not be split among multiple proxies to separate the votes.

2. วาระเลือกตั้งกรรมการสามารถเลือกตั้งกรรมการทั้งชุดหรือเลือกตั้งกรรมการเป็นรายบุคคล

In the agenda of appointment of directors, the directors may be elected as a whole slate or on an individual basis.

3. ในกรณีที่มีวาระที่จะพิจารณาในการประชุมมากกว่าวาระที่ระบุไว้ข้างต้น ผู้มอบฉันทะสามารถระบุเพิ่มเติมได้ในใบประจำต่อแบบหนังสือมอบฉันทะ (แบบ ค.) ตามแนบ

In the event that there are more agendas to be considered than those specified above, the proxy grantor may specify such additional agendas in the Annex to Proxy Form C as attached.

ใบประจำต่อแบบหนังสือมอบฉันทะ (แบบ ค.)

การมอบฉันทะในฐานะเป็นผู้ถือหุ้นของบริษัท ดีโอดี ไบโอเทค จำกัด (มหาชน)

ในการประชุมสามัญผู้ถือหุ้น ประจำปี 2569

ในวันศุกร์ที่ 10 เมษายน 2569 เวลา 14.00 น. ผ่านสื่ออิเล็กทรอนิกส์ (E-AGM)

Attachment to Proxy Form (Form C)

Proxy grant for the shareholder of DOD Biotech Public Company Limited

At the 2026 Annual General Meeting of Shareholders

on Friday, April 10, 2026, at 2:00 p.m. via Electronic Media (E-AGM)

วาระที่ เรื่อง.....

Agenda No..... Subject.....

 (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

The proxy is entitled to cast the votes on my/our behalf at its own discretion

 (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

The proxy must cast the votes in accordance with my following instructions

 เห็นด้วย.....เสียง ไม่เห็นด้วย.....เสียง งดออกเสียง.....เสียง

Approve votes Disapprove votes Abstain votes

วาระที่ เรื่อง.....

Agenda No..... Subject.....

 (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

The proxy is entitled to cast the votes on my/our behalf at its own discretion

 (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

The proxy must cast the votes in accordance with my following instructions

 เห็นด้วย.....เสียง ไม่เห็นด้วย.....เสียง งดออกเสียง.....เสียง

Approve votes Disapprove votes Abstain votes

วาระที่ เรื่อง.....

Agenda No..... Subject.....

 (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

The proxy is entitled to cast the votes on my/our behalf at its own discretion

 (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

The proxy must cast the votes in accordance with my following instructions

 เห็นด้วย.....เสียง ไม่เห็นด้วย.....เสียง งดออกเสียง.....เสียง

Approve votes Disapprove votes Abstain votes

วาระที่ พิจารณาอนุมัติการเสนอชื่อกรรมการ

Agenda No..... To consider and approve the appointment of the directors

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร
The proxy is entitled to cast the votes on my/our behalf at its own discretion

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้
The proxy must cast the votes in accordance with my following instructions

การแต่งตั้งกรรมการเป็นรายคณะ

Appointment of all directors

เห็นด้วย.....เสียง ไม่เห็นด้วย.....เสียง งออกเสียง.....เสียง
Approve votes Disapprove votes Abstain votes

การแต่งตั้งกรรมการเป็นรายบุคคล

Appointment of any director(s)

1) ชื่อกรรมการ.....

Name of Director:

เห็นด้วย.....เสียง ไม่เห็นด้วย.....เสียง งออกเสียง.....เสียง
Approve vote Disapprove votes Abstain votes

2) ชื่อกรรมการ.....

Name of Director:

เห็นด้วย.....เสียง ไม่เห็นด้วย.....เสียง งออกเสียง.....เสียง
Approve vote Disapprove votes Abstain votes

3) ชื่อกรรมการ.....

Name of Director:

เห็นด้วย.....เสียง ไม่เห็นด้วย.....เสียง งออกเสียง.....เสียง
Approve vote Disapprove votes Abstain votes

ข้าพเจ้าขอรับรองว่ารายการในใบประจำต่อแบบหนังสือมอบฉันทะ ถูกต้องบริบูรณ์และเป็นความจริงทุกประการ

I hereby certify that the statements in this Supplemental Proxy Form are correct, complete, and true in all respects.

ผู้มอบฉันทะ

The Grantor

ผู้รับมอบฉันทะ

The Proxy

ลงชื่อ.....

Signature

ลงชื่อ

Signature



The requisition form for the Annual Report (Form 56-1 One Report) in printed format

Dear Company Secretary

DOD Biotech Public Company Limited

I/We.....Age.....Year

Being a shareholder of DOD Biotech Public Company Limited, holding..... Shares

Address No..... Villa/Building.....Moo.....

Alley.....Road.....Sub-District.....

District.....Province.....Zipcode.....

Telephone number.....e-mail.....

Hereby to Request the Annual Report (Form 56-1 One Report) in printed format by sending the document to

Address No..... Villa/Building.....Moo.....

Alley.....Road.....Sub-District.....

District.....Province.....Zipcode.....

Remark:


- 1) Please submit this document to the company within 31 March 2026
- 2) Please submit this document to DOD Biotech Public Company Limited, No. 111, Moo. 2, Tha Chin Sub-district, Samut Sakhon District, Samut Sakhon Province. 74000
- 3) For more information, please call +66 34 446 333

Guidelines for attending of Electronic Meeting by Inventech Connect

Shareholders and proxies wishing to attend the meeting can proceed according to the procedure for submitting the request form to attend the meeting via electronic media as follows:

Step for requesting Username & Password from via e-Request system

1. The Shareholders must submit a request to attend the meeting by Electronic Means via Web Browser at <https://con.inventech.co.th/DOD456656R/#/homepage> or scan QR Code and follow the steps as shown in the picture



**** Merge user accounts, please using the same email and phone number ****

- 1 Click link URL or scan QR Code in the letter notice Annual General Meeting
- 2 Choose type request for request form to 4 step
Step 1 Fill in the information shown on the registration page
Step 2 Fill in the information for verify
Step 3 Verify via OTP
Step 4 Successful transaction, The system will display information again to verify the exactitude of the information
- 3 Please wait for an email information detail of meeting and Password


2. For Shareholders who would like to attend the Meeting either through the Electronic Means by yourself or someone who is not the provided independent directors, please note that the electronic registration will be available **April 2, 2026 at 8:30 a.m. and shall be closed on April 10, 2026 Until the end of the meeting.**
3. The electronic conference system will be available on **April 10, 2026 at 12:00 p.m.** (2 hours before the opening of the meeting). Shareholders or proxy holders shall use the provided Username and Password and follow the instruction manual to access the system.

Appointment of Proxy to the Company's Directors

For Shareholders who authorize one of the Company's Independent Directors to attend and vote on his or her behalf, The Shareholders can submit a request to attend the meeting by Electronic Means of the specified procedures or send the proxy form together with the required documents to the Company by mail to the following address. The proxy form and required documents shall be delivered to the Company by **9 April 2026 at 4.00 p.m.**

DOD Biotech Public Company Limited
Company Secretary
111 Moo 2 Thachin Sub-District, Muang Samutsakhon District,
Samutsakhon 74000

If you have any problems with the software,
please contact Inventech Call Center

 02-460-9225

 @inventechconnect




The system available during
2 – 10 April 2026
at 08.30 a.m. – 05.30 p.m.

(Specifically excludes holidays and public holidays)

Steps for registration for attending the meeting (e-Register) and voting process (e-Voting)

- 1 Get email and password that you received from
- 2 Click on “Register” button, the system has already registered and counted as a quorum. your email or request OTP
- 3 Click on “Join Attendance”, Then click on “Accept” button
- 4 Select which agenda that you want to vote
- 5 Click on “Vote” button
- 6 Click the voting button as you choose
- 7 The system will display status your latest vote




How to use
Inventech Connect



To cancel the last vote, please press the button “Cancel latest vote (This means that your most recent vote will be equal to not voting, or your vote will be determined by the agenda result) Shareholders can conduct a review of the votes on an agenda basis. When the voting results for that agenda are closed.

Step to ask questions via Inventech Connect




- Select which agenda
 - Click on “Question” button
- 1 Ask a question
 - Type the question then click “Send”
 - 2 Ask the question via video
 - Click on “Conference”
 - Click on “OK” for confirm your queue
 - Please wait for the queue for you then your can open the microphone and camera

* Note Operation of the electronic conferencing system and Inventech Connect systems. Check internet of shareholder or proxy include equipment and/or program that can use for best performance. Please use equipment and/or program as the follows to use systems.

1. Internet speed requirements
 - High-Definition Video: Must be have internet speed at 2.5 Mbps (Speed internet that recommend).
 - High Quality Video: Must be have internet speed at 1.0 Mbps.
 - Standard Quality Video: Must be have internet speed at 0.5 Mbps.
2. Equipment requirements.
 - Smartphone/Tablet that use IOS or android OS.
 - PC/Laptop that use Windows or Mac OS.
3. Requirement Browser Chrome (Recommend) / Safari / Microsoft Edge

**** The system does not supported internet explorer.**

Guidelines for attending of Electronic Meeting



In case Merge account/change account

In case filing request multiple by using the same email and phone number, the systems will merge account or in case user has more than 1 account, you can click on "Change account" and the previous account will still count the base in the meeting.

In case Exit the meeting

Attendees can click on "Register to leave the quorum", the systems will be number of your shares out from the meeting base.

Condition of use

The number of shares will be counted as a quorum

Additional documents to confirm the right to attend the 2026 Annual General Meeting by means of electronic channel (E-AGM), granting of proxy, and the cancellation of proxy

Shareholders and/or proxies who wish to attend the meeting via electronic media (E-Meeting) in this 2026 Annual General Shareholders' Meeting please attach additional documents to confirm you are right to attend the meeting as follows:

(1) In case of an individual shareholder attending the meeting in person

- A copy of "Identification document" of the shareholder with certified true copy

(2) In case of an individual shareholder appointed a proxy to attend the meeting instead

- A copy of "Identification document" of the shareholder with certified true copy
- A copy of "Identification document" of the proxy with certified true copy
- The Proxy form is attached with this invitation letter that has filled out the information correctly and completely with the signature of the grantor and the proxy

(3) In case of the shareholder is a juristic person having its representative under the affidavit attending the meeting

- A copy of "Identification document" of the representative of juristic shareholder with certified true copy
- A copy of the juristic shareholder's affidavit (Certificate is valid for not more than 1 year) and duly signed by the juristic representative including a message indicating that the representative who is attending the meeting has the power to act on behalf of that juristic person.

(4) In case of the shareholder is a juristic person appointing a proxy to attend the meeting

- The proxy form is attached with this invitation letter that has filled out the information correctly and completely which is signed by the grantor and the proxy
- A copy of "Identification document" of the proxy with certified true copy
- A copy of affidavit of the juristic person (Certificate valid for not more than 1 year), which is certified true copy by the corporate representative including a message showing that the representative of the juristic person who signed the proxy has the power to act on its behalf and a copy of the identification document of the juristic person's representative with certified true copy.

(5) In case of Non-Thai individual shareholder or Non-Thai juristic person established under foreign laws

The above details shall apply mutatis mutandis to shareholders or attendees who are Non-Thai or being a juristic person established under foreign law, as the case may be, subject to the following regulations:

- Affidavit of juristic person may be issued by the government agency of the country in which such juristic person is located or by an officer of that juristic person (Certificate is valid for not more than 1 year). In order that the affidavit of the juristic person must comprise the details regarding its name, name of the authorized signatory to bind the juristic person and conditions or restrictions on the power to sign together with its head office location.
- Original documents which are not in English must be accompanied by an English translation and the representative of the juristic person has to certify the accuracy of the translation (if any).

(6) In case of the shareholder is a foreign investor and appoints a custodian in Thailand to be a shared depository and appointed the proxy according to the Proxy Form C.

- Proxy Form C which has been completely filled out and signed the name of the proxy grantor and the proxy
- Confirmation letter which confirms that the person signing the proxy is authorized to operate a custodian business.
- A copy of the Custodian juristic person registration certificate which is certified true copy by the representative of the juristic person with a company seal (if any) and a message indicating that representative of the juristic person who signs as the proxy has the power to act on behalf of the Custodian
- Copy of documents issued by government agencies of the juristic person representative as in the case of shareholders who are individual persons with certified true copy
- A valid power of attorney of foreign investors appointed the custodian as depository of shares
- A copy of affidavit or certificate of incorporation of the shareholder's juristic person that has been certified as true and correct by the authorized representative with the company's seal (if any), which indicates that the authorized representative has been empowered to act on behalf of the juristic person who is a shareholder.
- Copy of documents issued by government agencies of the authorized representative of the juristic person as same as where applicable for individual persons with certified true copy

Remarks:

- Identification documents must be government- issued, contain a photograph, and remain valid. Acceptable documents include, but are not limited to, a national identification card, government official ID card, state enterprise employee ID card, driver's license, passport, or other official identification issued by a government agency.
- Shareholders are advised to review the details of the meeting agenda before deciding to grant a proxy.
- If you wish to revoke the proxy authorization, you may do so by notifying the Chairman in writing via email at cs@dodbiotech.com no later than April 9, 2026.
- The company reserves the right to deny participation in the Annual General Meeting of Shareholders if the shareholder or proxy holder fails to provide valid and complete documentation as required under the above conditions. The company's decision in this regard shall be deemed final.

Privacy Notice for the Shareholders' Meeting

DOD Biotech Public Company Limited (the “Company”) recognizes the importance of maintaining the confidentiality of personal information of shareholders and/or proxies. This privacy notice, pursuant to the Personal Data Protection Act B.E. 2562 (2019), shall be applied for the collection, use, disclosure, and processing of personal data to verify the identity of shareholders and/or proxies directly and/or indirectly. The detail is as follows:

1. Personal Data to be Collected

The Company will obtain and collect personal data directly from shareholders and/or proxies and from Thailand Securities Depository Company Limited (“TSD”), who is the company's share registrar. Personal data consists of as follows:

- 1.1 General Personal Data such as name, surname, identification number, date of birth, gender, shareholder identification number, amount of shares, photo, video footage taken at our premises as well as health information and travel history to achieve the objectives of health care to prevent the Coronavirus Disease 2019 (COVID-19).
- 1.2 Contact Information such as address, telephone number, and email.

Remark: clarification of documents for registration and/or appointment of proxy which the shareholders and/or proxies submitted to the Company which may contain sensitive data such as nationality, blood group, religious are unnecessary information for the Shareholder Meeting. The Company would like to inform that the Company is not intended to collect sensitive data, therefore before submit the documents to the Company, the shareholders and/or proxies can cross out or make the information invisible to conceal the sensitive data. In the event that the shareholders and/or proxies have not concealed such sensitive data, the Company reserves its rights to conceal such sensitive data on the received documents without considering the Company has collected the sensitive data.

2. Purpose of Collection, Use and Disclosure of Personal Data

The Company is required to collect, use, and discloses personal data of the shareholders and/or proxies for the following purposes:

- 2.1 For the benefits of calling, arranging and conducting the Annual General Meeting of Shareholders of the Company pursuant to the Company's Articles of Association as well as applicable laws, notifications and criteria for meeting arrangement as stipulated by the government.
- 2.2 For delivery of the Annual Report and/or prepare minutes of the General Meeting to the shareholders.
- 2.3 For the benefits of registration to attend the General Meeting of Shareholders, quorum counting, voting and counting of votes in the General Meeting of Shareholders.
- 2.4 To be used for screening attendees who are at risk for COVID-19 to achieve public health objectives for the prevention of dangerous communicable diseases and to comply with the measures and guidelines for meeting arrangement as prescribed by the government.

3. Persons to whom the Company could disclose personal data of the shareholders and/or proxies

The Company may disclose the personal data of the shareholders and/or proxies to persons or entities concerned as follows:

- 3.1 Consultant or service provider who the Company hires to conduct the Meeting and process personal data of the shareholders and/or proxies.
- 3.2 Government agencies or regulators to preform duties in accordance with the law related to the Company such as Department of Business Development, Ministry of Commerce, The Securities and Exchange Commission and The Stock Exchange of Thailand.

3.3 Government agencies involved in public health and prevention of communicable diseases, In case of health-related necessity such as Department of Disease Control of Thailand or other related agencies.

3.4 Website of the Company, for publish photos and/or video from the General Meeting of Shareholders and minutes of the General Meeting of Shareholders.

4. Rights of Data Subjects

Pursuant to the applicable laws, the data subjects have the rights, pursuant to the Personal Data Protection Act B.E. 2562 (2019), which includes the right to withdraw consent, to request access to and obtain a copy of their personal data or to request the disclosure of the acquisition of the personal data without consent, to request for transferring the personal data to other person as specified by laws, to object the collection, use, or disclosure of the personal data, to request for deletion or destruction of their personal data or anonymize the personal data to become the anonymous data which cannot identify the data subject, to restrain the use of personal data, to request for making personal data to be accurate, up-to-date and not misleading, and to file a complaint in the event that the data controller or the data processor violates or does not comply with the Personal Data Protection Act. In order that in accordant with the relevant laws.

5. Personal Data Retention Period

The Company will retain personal data under item 1 within the period required by applicable laws and/ or as long as it is reasonably to achieve the purpose under item 2.

6. Contact Information

Company Secretary

DOD Biotech Public Company Limited

Address: 111 Moo 2 Thachin Sub-District, Muang Samutsakhon
District Samutsakhon 74000

Tel : +66 (0) 34 446 333, +66 (0) 34 446 444

E-mail : cs@dodbiotech.com